Calendula Thuja
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2018-08-10
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 00:52:52
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Under age 2: Consult a doctor.
DOSAGE & ADMINISTRATION SECTION
Directions: Fill the provided applicator with 2 to 3 grams of gel and apply at bedtime for 14 nights.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Calendula 2X, Echinacea (Purple coneflower) 2X, Marjorana (Marjoram) 2X, Lilium tigrinum (Tiger lily) 3X, Thuja (American arborvitae) 3X, Kreosotum (Creosote) 6X, Pulsatilla (Pasqueflower) 6X, Argentum colloidal (Colloidal silver) 7X, Candida albicans (Yeast) 33X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Distilled water, Glycerin, Sodium alginate, Lactic acid, Eucalyptus oil, Rosemary oil, Sage oil, Thyme oil, Tea tree oil, Grapefruit seed extract
OTC - PURPOSE SECTION
Use: Temporary relief of vaginal itching and irritation.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions, if conditions worsen or persist, or accidental ingestion occurs. If pregnant or nursing consult a doctor before use. Avoid contact with eyes. Do not use if safety seals on box are broken or missing. BEST WHEN USED WITHIN 30 DAYS OF OPENING.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858 Made with care by Uriel, East Troy, WI 53120
www.urielpharmacy.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 48951-3204-8 | 2023-09-25 | C162847 | 48780-1 | 9d75b9d0-ba61-f424-e053-dadaa90a57ce | Calendula Thuja |
| 48951-3204-8 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-ba61-f424-e053-dadaa90a57ce | Calendula Thuja |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CALENDULA OFFICINALIS FLOWERING TOP | ACTIVE INGREDIENT | 18E7415PXQ | 1 | |
| CANDIDA ALBICANS | ACTIVE INGREDIENT | 4D7G21HDBC | 1 | |
| ECHINACEA, UNSPECIFIED | ACTIVE INGREDIENT | 4N9P6CC1DX | 1 | |
| LILIUM LANCIFOLIUM WHOLE FLOWERING | ACTIVE INGREDIENT | X67Z2963PI | 1 | |
| ORIGANUM MAJORANA WHOLE | ACTIVE INGREDIENT | R40XM3HU5X | 1 | |
| PULSATILLA VULGARIS | ACTIVE INGREDIENT | I76KB35JEV | 1 | |
| SILVER | ACTIVE INGREDIENT | 3M4G523W1G | 1 | |
| THUJA OCCIDENTALIS WHOLE | ACTIVE INGREDIENT | 5HBV6WCE3N | 1 | |
| WOOD CREOSOTE | ACTIVE INGREDIENT | 3JYG22FD73 | 1 | |
| CALENDULA OFFICINALIS FLOWERING TOP | ACTIVE MOIETY | 18E7415PXQ | 1 | |
| CANDIDA ALBICANS | ACTIVE MOIETY | 4D7G21HDBC | 1 | |
| ECHINACEA, UNSPECIFIED | ACTIVE MOIETY | 4N9P6CC1DX | 1 | |
| LILIUM LANCIFOLIUM WHOLE FLOWERING | ACTIVE MOIETY | X67Z2963PI | 1 | |
| ORIGANUM MAJORANA WHOLE | ACTIVE MOIETY | R40XM3HU5X | 1 | |
| PULSATILLA VULGARIS | ACTIVE MOIETY | I76KB35JEV | 1 | |
| SILVER | ACTIVE MOIETY | 3M4G523W1G | 1 | |
| THUJA OCCIDENTALIS WHOLE | ACTIVE MOIETY | 5HBV6WCE3N | 1 | |
| WOOD CREOSOTE | ACTIVE MOIETY | 3JYG22FD73 | 1 | |
| CITRUS PARADISI SEED | INACTIVE INGREDIENT | 12F08874Y7 | 1 | |
| EUCALYPTUS OIL | INACTIVE INGREDIENT | 2R04ONI662 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| LACTIC ACID | INACTIVE INGREDIENT | 33X04XA5AT | 1 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 1 | |
| ROSEMARY OIL | INACTIVE INGREDIENT | 8LGU7VM393 | 1 | |
| SAGE OIL | INACTIVE INGREDIENT | U27K0H1H2O | 1 | |
| SODIUM ALGINATE | INACTIVE INGREDIENT | C269C4G2ZQ | 1 | |
| THYME OIL | INACTIVE INGREDIENT | 2UK410MY6B | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- Calendula Thuja
- CITRUS PARADISI SEED
- CALENDULA OFFICINALIS FLOWERING TOP
- ECHINACEA, UNSPECIFIED
- ORIGANUM MAJORANA WHOLE
- LILIUM LANCIFOLIUM WHOLE FLOWERING
- THUJA OCCIDENTALIS WHOLE
- WOOD CREOSOTE
- PULSATILLA VULGARIS
- SILVER
- CANDIDA ALBICANS
- TEA TREE OIL
- WATER
- GLYCERIN
- SODIUM ALGINATE
- LACTIC ACID
- EUCALYPTUS OIL
- ROSEMARY OIL
- SAGE OIL
- THYME OIL
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-3204 | 48951-3204-8 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CONCENTRATE / ORAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | SUPPOSITORY / VAGINAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | EMULSION / OPHTHALMIC | 0.47 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TROCHE / ORAL | 525 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TABLET, EXTENDED RELEASE / ORAL | 627 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | INJECTION / INTRAVENOUS | 2232 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TABLET / ORAL | 480 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | SYRUP / ORAL | 3 mg/1ml | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SUSPENSION / ORAL | 400 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | CREAM / VAGINAL | 0.81 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | POWDER, FOR SUSPENSION / ORAL | 19 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | SUSPENSION / ORAL | 49 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | LOTION / TOPICAL | 5.7 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, EXTENDED RELEASE / ORAL | 265 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SYRUP / ORAL | 2 mg/1ml | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | INJECTION, SOLUTION / INTRAVENOUS | 87 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | LIQUID / TOPICAL | 0.25 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET / ORAL | 6 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | LOTION / TOPICAL | 0.2 %w/w | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | SUSPENSION / TOPICAL | 0.7 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION/ DROPS / OPHTHALMIC | 0.47 %w/v | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | GEL / TOPICAL | 30 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, COATED / ORAL | NA | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | TABLET / ORAL | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 063154fc-8365-5d47-e063-6294a90ad23f | 029d43dd-1c1d-4f81-a3c4-68191aa07728 | 2023-09-25 | Warnings | 029d43dd-1c1d-4f81-a3c4-68191aa07728 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
